Hong KongInventionsPatentpatent application
2026年4月13日

Please “Mind the Traps”: Four Common Misconceptions About Hong Kong Patents

by
黃惠盈女士
王怡瑾女士
車李曉芸女士

For many foreign companies interested in the broader Asian market, Hong Kong is a strategically important jurisdiction. However, because of its unique legal framework, domestic and foreign companies alike are confused by how IP protection works in Hong Kong. Missteps in such understanding can lead to critical, costly "gaps" in IP protection.

To safeguard innovations effectively in Hong Kong, be aware of these four common misconceptions:

  • Trap 1: "Our Mainland China patent automatically covers Hong Kong."
    • The Reality: Under the "One Country, Two Systems" principle, Hong Kong operates as an entirely independent jurisdiction. A patent granted in China (by the China National Intellectual Property Administration (CNIPA)) has no legal effect in Hong Kong.
    • The Strategy: Proactively file a separate application with the Hong Kong Intellectual Property Department (HKIPD). Treat Hong Kong as a separate jurisdiction in your global IP portfolio to ensure comprehensive regional protection. You can file directly with the HKIPD or request to record and register a Chinese, UK, or European (designating the UK) patent in Hong Kong without having to do a separate substantive examination in Hong Kong.
  • Trap 2: "We can use our PCT application for direct entry into Hong Kong."
    • The Reality: Patent Cooperation Treaty (PCT) applications cannot enter Hong Kong directly via the national phase entry.
    • The Strategy: First, enter the national or regional phase in China, the UK, or Europe (designating the UK). Then, you can subsequently extend that national or regional phase application into Hong Kong.
  • Trap 3: "We can file only one Re-registration patent application for every invention in Hong Kong."
    • The Reality: You can file (“record”) more than one standard Hong Kong (R) patent  application for the same invention designating multiple jurisdictions (e.g., China and Europe) respectively, and register them all to proceed to grant, provided no two claims have substantively identical claim scopes (double patenting). 
    • The Strategy: Obtaining a Standard (R) patent in Hong Kong involves a two steps process: Step 1: Request to record (at publication of CN/EP/UK patent application) and Step 2: Request for registration (at grant of CN/EP/UK patent). You can request to record multiple Step 1 requests and file the Step 2 request for the application that is granted with a more favourable claim scope.  Alternatively, you may be able to register multiple Step 1 applications, provided no two granted claims have substantively identical claim scopes (double patenting). 
  • Trap 4: “Our only option for getting a patent in Hong Kong is the standard 20-year patent”
    • The Reality: Hong Kong short-term patents are excellent alternatives for fast-moving commercial technologies. They grant quickly because they are not substantively examined, and are valid for up to eight years.
    • The Strategy: For products with a short market life or fast turnover, the Hong Kong short-term patent can be a great choice. A maximum of two independent claims can be included in one application. Please note: although a Hong Kong short-term is not examined, a substantive search report (even if negative) will be issued and published alongside the granted patent.

Hong Kong IP protection goes well beyond a simple registration of a Chinese or European/UK patent. There are many strategies and multi-layered approaches for protecting IP in this key jurisdiction.

If you would like to have more information on this matter or would like to have our advice, please feel free to contact us at [email protected].

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

2023年12月12日
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

Inventive Step for an Enantiomer over a Racemate: “L-ornidazole” Patent Invalidation Case

2023年11月27日
Each year, China’s Supreme People’s Court (SPC) issues its annual “Judgment Digests”, which includes a list of “48 typical cases” highlighting representative SPC decisions in the previous year. The Judgment Digests help us understand more about the SPC’s judicial ideology, trial concepts, and adjudication methods in dealing with difficult and sophisticated legal issues as well […]

CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

2021年12月6日
In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even […]

China Divisional Practice

2019年6月17日
China allows the filing of divisional applications but under specific circumstances. Most importantly, divisional applications can usually only be filed voluntarily during the prosecution of the original parent application. Once the parent application is granted or withdrawn, no additional voluntary divisional applications may be filed. However, divisionals can be filed to pursue subject matter not […]

我們過去活動

Top crossarrow-right